Clinical trial
An Open-Label, Parallel-Controlled, Multi-Center Phase Ib/IIa Clinical Study to Evaluate the Efficacy and Safety of Purinostat Mesylate for Injection Combined With Pomalidomide Capsules and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
NCT06484829 is registered in ClinicalTrials.gov with Chengdu Zenitar Biomedical Technology Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Parallel-Controlled, Multi-Center Phase Ib/IIa Clinical Study to Evaluate the Efficacy and Safety of Purinostat Mesylate for Injection Combined With Pomalidomide Capsules and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
- Lead sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- March 25, 2024
- Completion date
- April 1, 2026
- Enrollment
- 144 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed or refractory multiple myeloma (rrmm)